logo
logo

Lysoway Therapeutics has received a $2.93 million grant from The Michael J. Fox Foundation to advance its TRPML1 agonist for Parkinson's disease treatment.

Aug 06, 2025•2 days ago

Amount Raised

$2.93 Million

Round Type

seed

CambridgeBiopharmaTherapeuticsBiotechnologyHealth Care

Investors

The Michael J. Fox Foundation

Description

Lysoway Therapeutics, a biopharmaceutical company, announced a research grant from The Michael J. Fox Foundation for Parkinson's Research. The $2.93 million funding will support the development of their TRPML1 agonist. The goal is to initiate first-in-human clinical trials in early 2026

Company Information

Company

Lysoway Therapeutics

Location

Cambridge, Massachusetts, United States

About

Lysoway Therapeutics, Inc. is a biopharmaceutical company developing small molecule modulators of lysosomal ion channels. The company is focused on advancing a pipeline of small molecule activators targeting these channels to treat neurodegenerative diseases. Lysoway aims to develop therapeutically viable solutions to slow or halt disease progression.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers